Abstract

BACKGROUND:: Neurophysiological measures of brain function, such as magnetoencephalography (MEG), are widely used in clinical neurology and have strong relations with cognitive impairment and dementia but are still underdeveloped in multiple sclerosis (MS).

OBJECTIVES:: To demonstrate the value of clinically applicable MEG-measures in evaluating cognitive impairment in MS.

METHODS:: In eyes-closed resting-state, MEG data of 83 MS patients and 34 healthy controls (HCs) peak frequencies and relative power of six canonical frequency bands for 78 cortical and 10 deep gray matter (DGM) areas were calculated. Linear regression models, correcting for age, gender, and education, assessed the relation between cognitive performance and MEG biomarkers.

RESULTS:: Increased alpha1 and theta power was strongly associated with impaired cognition in patients, which differed between cognitively impaired (CI) patients and HCs in bilateral parietotemporal cortices. CI patients had a lower peak frequency than HCs. Oscillatory slowing was also widespread in the DGM, most pronounced in the thalamus.

CONCLUSION:: There is a clinically relevant slowing of neuronal activity in MS patients in parietotemporal cortical areas and the thalamus, strongly related to cognitive impairment. These measures hold promise for the application of resting-state MEG as a biomarker for cognitive disturbances in MS in a clinical setting.

Original languageEnglish
Pages (from-to)1352458518810260
JournalMultiple Sclerosis Journal
DOIs
Publication statusE-pub ahead of print - 22 Nov 2018

Cite this

@article{251b350f41ff4052a62b501993eaa38c,
title = "Resting-state MEG measurement of functional activation as a biomarker for cognitive decline in MS",
abstract = "BACKGROUND:: Neurophysiological measures of brain function, such as magnetoencephalography (MEG), are widely used in clinical neurology and have strong relations with cognitive impairment and dementia but are still underdeveloped in multiple sclerosis (MS).OBJECTIVES:: To demonstrate the value of clinically applicable MEG-measures in evaluating cognitive impairment in MS.METHODS:: In eyes-closed resting-state, MEG data of 83 MS patients and 34 healthy controls (HCs) peak frequencies and relative power of six canonical frequency bands for 78 cortical and 10 deep gray matter (DGM) areas were calculated. Linear regression models, correcting for age, gender, and education, assessed the relation between cognitive performance and MEG biomarkers.RESULTS:: Increased alpha1 and theta power was strongly associated with impaired cognition in patients, which differed between cognitively impaired (CI) patients and HCs in bilateral parietotemporal cortices. CI patients had a lower peak frequency than HCs. Oscillatory slowing was also widespread in the DGM, most pronounced in the thalamus.CONCLUSION:: There is a clinically relevant slowing of neuronal activity in MS patients in parietotemporal cortical areas and the thalamus, strongly related to cognitive impairment. These measures hold promise for the application of resting-state MEG as a biomarker for cognitive disturbances in MS in a clinical setting.",
author = "Schoonhoven, {Deborah N} and Matteo Fraschini and Prejaas Tewarie and Uitdehaag, {Bernard Mj} and Eijlers, {Anand Jc} and Geurts, {Jeroen Jg} and Arjan Hillebrand and Schoonheim, {Menno M} and Stam, {Cornelis J} and Strijbis, {Eva Mm}",
year = "2018",
month = "11",
day = "22",
doi = "10.1177/1352458518810260",
language = "English",
pages = "1352458518810260",
journal = "Multiple Sclerosis Journal",
issn = "1352-4585",
publisher = "SAGE Publications",

}

TY - JOUR

T1 - Resting-state MEG measurement of functional activation as a biomarker for cognitive decline in MS

AU - Schoonhoven, Deborah N

AU - Fraschini, Matteo

AU - Tewarie, Prejaas

AU - Uitdehaag, Bernard Mj

AU - Eijlers, Anand Jc

AU - Geurts, Jeroen Jg

AU - Hillebrand, Arjan

AU - Schoonheim, Menno M

AU - Stam, Cornelis J

AU - Strijbis, Eva Mm

PY - 2018/11/22

Y1 - 2018/11/22

N2 - BACKGROUND:: Neurophysiological measures of brain function, such as magnetoencephalography (MEG), are widely used in clinical neurology and have strong relations with cognitive impairment and dementia but are still underdeveloped in multiple sclerosis (MS).OBJECTIVES:: To demonstrate the value of clinically applicable MEG-measures in evaluating cognitive impairment in MS.METHODS:: In eyes-closed resting-state, MEG data of 83 MS patients and 34 healthy controls (HCs) peak frequencies and relative power of six canonical frequency bands for 78 cortical and 10 deep gray matter (DGM) areas were calculated. Linear regression models, correcting for age, gender, and education, assessed the relation between cognitive performance and MEG biomarkers.RESULTS:: Increased alpha1 and theta power was strongly associated with impaired cognition in patients, which differed between cognitively impaired (CI) patients and HCs in bilateral parietotemporal cortices. CI patients had a lower peak frequency than HCs. Oscillatory slowing was also widespread in the DGM, most pronounced in the thalamus.CONCLUSION:: There is a clinically relevant slowing of neuronal activity in MS patients in parietotemporal cortical areas and the thalamus, strongly related to cognitive impairment. These measures hold promise for the application of resting-state MEG as a biomarker for cognitive disturbances in MS in a clinical setting.

AB - BACKGROUND:: Neurophysiological measures of brain function, such as magnetoencephalography (MEG), are widely used in clinical neurology and have strong relations with cognitive impairment and dementia but are still underdeveloped in multiple sclerosis (MS).OBJECTIVES:: To demonstrate the value of clinically applicable MEG-measures in evaluating cognitive impairment in MS.METHODS:: In eyes-closed resting-state, MEG data of 83 MS patients and 34 healthy controls (HCs) peak frequencies and relative power of six canonical frequency bands for 78 cortical and 10 deep gray matter (DGM) areas were calculated. Linear regression models, correcting for age, gender, and education, assessed the relation between cognitive performance and MEG biomarkers.RESULTS:: Increased alpha1 and theta power was strongly associated with impaired cognition in patients, which differed between cognitively impaired (CI) patients and HCs in bilateral parietotemporal cortices. CI patients had a lower peak frequency than HCs. Oscillatory slowing was also widespread in the DGM, most pronounced in the thalamus.CONCLUSION:: There is a clinically relevant slowing of neuronal activity in MS patients in parietotemporal cortical areas and the thalamus, strongly related to cognitive impairment. These measures hold promise for the application of resting-state MEG as a biomarker for cognitive disturbances in MS in a clinical setting.

U2 - 10.1177/1352458518810260

DO - 10.1177/1352458518810260

M3 - Article

SP - 1352458518810260

JO - Multiple Sclerosis Journal

JF - Multiple Sclerosis Journal

SN - 1352-4585

ER -